TG Therapeutics (STU:NKB2) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 28, 2024)

View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

TG Therapeutics (STU:NKB2) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

TG Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (STU:NKB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

TGTX:USA NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines